Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regulatory filings from an ophthalmic device maker can feel as technical as a surgical manual. Sight Sciences’ 10-K alone dives into FDA clearance pathways, real-world data for the OMNI Surgical System, and reimbursement hurdles for TearCare. Missing one paragraph could mean overlooking a projected shift in surgeon adoption or a new clinical-trial milestone.
Stock Titan answers that problem instantly. Our AI parses every Sight Sciences SEC filing the moment it posts to EDGAR—whether it is a Sight Sciences quarterly earnings report 10-Q filing or an unexpected Sight Sciences 8-K material events explained. You’ll get plain-English summaries, key financial tables, and red-flag alerts on regulatory updates, so you can focus on decisions, not page counts.
Need real-time trading intelligence? Follow Sight Sciences insider trading Form 4 transactions in minutes, complete with contextual commentary on executive behavior. Digging into growth drivers? Our platform links OMNI unit sales and TearCare placement figures straight from the Sight Sciences annual report 10-K simplified. Curious about leadership pay? The Sight Sciences proxy statement executive compensation is decoded so you can compare incentive structures to clinical performance.
- AI-powered highlights for every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A
- Form 4 insider alerts: Sight Sciences Form 4 insider transactions real-time
- Side-by-side earnings trend charts and Sight Sciences earnings report filing analysis
Understanding Sight Sciences SEC documents with AI means knowing exactly when clinical data, reimbursement shifts, or executive stock transactions Form 4 could reshape the outlook for this innovative MIGS and dry-eye pioneer—no medical jargon required.
Sight Sciences announced that two Medicare Administrative Contractors, Novitas and FCSO, established jurisdiction-wide pricing for CPT 0563T, which describes the TearCare procedure. The Medicare fee schedule amount is $1,141.59, effective for dates of service on and after January 1, 2025, across all Novitas and FCSO jurisdictions.
The local fee schedules are active for claim processing and are expected to be posted on the Novitas and FCSO websites. TearCare claims in these areas will be payable based on individual medical necessity determinations. The regions covered by these MACs have an estimated 10.4 million total covered lives. The company also posted an investor presentation and plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.
Sight Sciences, Inc. reporting person Brenton Taylor disclosed a sale of 591 shares of common stock on
Sight Sciences, Inc. filing a Form 144 reports a proposed sale of 591 common shares with an aggregate market value of
Sight Sciences (SGHT) disclosed an insider transaction by its Chief Financial Officer. On 10/02/2025, the officer reported a sale of 19,948 shares of common stock at $3.3 per share, coded “S.” Following the transaction, the officer directly holds 597,520 shares.
The filing notes the shares were sold to cover the reporting person’s tax liability associated with the vesting of restricted stock units. This reflects a routine tax-related disposition rather than a discretionary portfolio trade.
Sight Sciences (SGHT) President & CEO, Director, and 10% owner Paul Badawi reported a sale of common stock on 10/01/2025. He sold 24,441 shares at $3.34 per share (Code S), as noted in the filing’s footnote, to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi beneficially owns 5,962,502 shares of Sight Sciences common stock directly. The filing indicates the disposition was related to tax withholding tied to equity compensation vesting.
David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.
This Form 144 for Sight Sciences, Inc. (SGHT) notifies a proposed sale of 9,731 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $31,848.59, with an approximate sale date of 10/03/2025. The shares were acquired on 09/30/2025 through restricted stock vesting and the acquisition payment is listed as compensation. The filing also discloses a prior sale by Jeremy Hayden of 9,160 common shares on 07/03/2025 for gross proceeds of $38,235.67. The filer represents, by signing, that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 filing: A shareholder filed a notice to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 10/03/2025. The filing lists an aggregate market value of $49,276.20 for the proposed sale.
The shares were acquired via restricted stock vesting: 11,236 shares on 10/17/2024 and 3,764 shares on 10/18/2024, recorded as compensation. Shares outstanding were 52,367,359 at the time cited.
Recent activity over the past three months shows sales by Matthew Link of common stock: 10,000 shares for $35,227.21 on 09/12/2025; 15,990 shares for $55,291.81 on 09/16/2025; 20,000 shares for $73,400.00 on 09/19/2025; and 20,753 shares for $73,350.73 on 09/23/2025.
Sight Sciences, Inc. (SGHT) Form 144 summary: The filing notifies a proposed sale of 19,948 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $65,750.60. The sale is scheduled for 10/02/2025 on NASDAQ and the issuer reports 52,367,359 shares outstanding. The shares were acquired on 09/30/2025 through restricted stock vesting and were recorded as compensation. The filer also disclosed a prior sale of 19,260 shares on 07/02/2025 that generated $78,933.26 in gross proceeds. The notice includes the standard signature representation that the seller is unaware of undisclosed material adverse information.
Sight Sciences, Inc. (SGHT) Form 144 filing reports a proposed sale of 24,441 common shares through Fidelity Brokerage Services LLC on Nasdaq. The shares were acquired by restricted stock vesting on 09/30/2025 and are identified as compensation. The filer reports 52,367,359 shares outstanding for the class, and records an approximate aggregate market value of $81,740.48 for the shares to be sold with an approximate sale date of 10/01/2025. The filing also discloses that Paul Badawi sold 23,637 common shares on 07/01/2025 for gross proceeds of $98,133.73. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
